Share on StockTwits

Thoratec (NASDAQ:THOR)‘s stock had its “outperform” rating reiterated by Leerink Swann in a research note issued on Thursday. They currently have a $35.00 price target on the stock, down from their previous price target of $40.00. Leerink Swann’s price target would suggest a potential upside of 7.46% from the company’s current price.

THOR has been the subject of a number of other recent research reports. Analysts at Oppenheimer cut their price target on shares of Thoratec from $41.00 to $35.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at BTIG Research downgraded shares of Thoratec from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, analysts at Credit Suisse downgraded shares of Thoratec from an “outperform” rating to a “neutral” rating in a research note on Thursday. They now have a $27.00 price target on the stock, down previously from $40.00. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Thoratec has an average rating of “Buy” and an average target price of $37.75.

Thoratec (NASDAQ:THOR) traded down 28.89% on Thursday, hitting $23.16. The stock had a trading volume of 5,272,129 shares. Thoratec has a 52-week low of $30.01 and a 52-week high of $43.58. The stock’s 50-day moving average is $33.47 and its 200-day moving average is $34.09. The company has a market cap of $1.315 billion and a price-to-earnings ratio of 25.65.

Thoratec (NASDAQ:THOR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.43 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.43. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $128.30 million. During the same quarter last year, the company posted $0.52 earnings per share. Thoratec’s revenue was down 9.5% compared to the same quarter last year. On average, analysts predict that Thoratec will post $1.75 earnings per share for the current fiscal year.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.